Yakar Nil, Unlu Ozge, Cen Lujia, Hasturk Hatice, Chen Tsute, Shi Wenyuan, He Xuesong, Kantarci Alpdogan
Immunology and Infectious Diseases, The ADA Forsyth Institute, Cambridge, MA, USA.
Faculty of Science, Basic and Industrial Microbiology Section, Ege University, Izmir, Turkey.
J Oral Microbiol. 2024 Aug 12;16(1):2388900. doi: 10.1080/20002297.2024.2388900. eCollection 2024.
, a pathobiont in periodontal disease, contributes to alveolar bone destruction. We assessed the efficacy of a new targeted antimicrobial, FP-100, in eradicating from the oral microbial community and and evaluated its effectiveness in reducing bone loss in a mouse periodontitis model.
A multispecies bacterial community was cultured and treated with two concentrations of FP-100 over two days. Microbial profiles were examined at 24-h intervals using 16S rRNA sequencing. A ligature-induced periodontitis mouse model was employed to test FP-100 in vivo.
FP-100 significantly reduced . within the in vitro community ( < 0.05) without altering microbial diversity at a 2 μM concentration. In mice, cultivable was undetectable in FP-100-treated ligatures but persistent in controls. Beta diversity plots showed distinct microbial structures between treated and control mice. Alveolar bone loss was significantly reduced in the FP-100 group ( = 0.018), with concurrent decreases in gingival IL-1β and TNF-α expression ( = 0.052 and 0.018, respectively).
FP-100 effectively eliminates from oral microbiota and significantly reduces bone loss in a mouse periodontitis model, demonstrating its potential as a targeted therapeutic agent for periodontal disease.
作为牙周病中的一种机会致病菌，可导致牙槽骨破坏。我们评估了一种新型靶向抗菌药物FP - 100在根除口腔微生物群落中的 以及 方面的疗效，并在小鼠牙周炎模型中评估了其减少骨质流失的有效性。
培养多物种细菌群落，并在两天内用两种浓度的FP - 100进行处理。每隔24小时使用16S rRNA测序检查微生物谱。采用结扎诱导的牙周炎小鼠模型在体内测试FP - 100。
在体外群落中，FP - 100在2 μM浓度下显著减少了 （ < 0.05），且未改变微生物多样性。在小鼠中，在经FP - 100处理的结扎部位未检测到可培养的 ，但在对照组中持续存在。β多样性图显示处理组和对照组小鼠之间存在明显的微生物结构差异。FP - 100组的牙槽骨流失显著减少（ = 0.018），同时牙龈IL - 1β和TNF - α表达也相应降低（分别为 = 0.052和0.018）。
FP - 100能有效从口腔微生物群中清除 ，并在小鼠牙周炎模型中显著减少骨质流失，证明其作为牙周病靶向治疗药物的潜力。
